EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection

Soumya Shanta Mohanty, R R Selvammathy, Hindustan Abdul Ahad, Edukulla Satheesh Kumar

Indian Journal of Pharmacology · 2026-07 · 58 (4) · 293-306

DOI: 10.4103/ijp.ijp_1384_25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Pharmacology, online erschienen am 01.07.2026. Verfasst von Soumya Shanta Mohanty und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, R R College of Pharmacy, Bengaluru, Karnataka, India. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among the various treatments for type 2 diabetes during the initial period, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been considered together as agents with separate cardiometabolic benefits, given their limited glucose-lowering effects. GLP-1 RAs are reported to inhibit atherosclerosis through several physiological processes, including increased blood flow in endothelial tissues, decreased inflammation, increased antioxidant levels, and improved lipid profile. There is a similar situation with SGLT2 inhibitors, and the explanation for this is different yet complementary, as these drugs cause a decrease in both cardiac preload and afterload and, at the same time, increase vascular permeability, diuresis, and more efficient energy usage by the heart. Thus, they have been affirmed by extensive clinical trials, which show that, although these drugs may harm patients, they do not result in significant cardiovascular events, have a lower treatment rate for heart defects, and are associated with a longer time before the patient’s renal function deteriorates. This translates into a continuing shift toward the dominion in terms of cardiometabolic protection – a strategy that is receiving strong backing from the majority of clinical guidelines across the world.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansAnimalsDrug Therapy, Combination

Stichwörter der Autor:innen

Atherosclerosiscardio metabolic diseaseglucagon-like peptide-1 receptorstherapy

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Pharmacy Practice, R R College of Pharmacy, Bengaluru, Karnataka, India.
  • Department of Pharmaceutics, R R College of Pharmacy, Bengaluru, Karnataka, India.

Zitieren

APA

Mohanty, S. S., Selvammathy, R. R., Ahad, H. A., & Kumar, E. S. (2026). Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection. Indian Journal of Pharmacology, 58(4), 293-306. https://doi.org/10.4103/ijp.ijp_1384_25

Vancouver

Mohanty SS, Selvammathy RR, Ahad HA, Kumar ES. Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection. Indian Journal of Pharmacology. 2026;58(4):293-306. doi:10.4103/ijp.ijp_1384_25

BibTeX
@article{Mohanty2026,
  author = {Mohanty, Soumya Shanta and Selvammathy, R R and Ahad, Hindustan Abdul and Kumar, Edukulla Satheesh},
  title = {Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection},
  journal = {Indian Journal of Pharmacology},
  year = {2026},
  volume = {58},
  number = {4},
  pages = {293--306},
  doi = {10.4103/ijp.ijp_1384_25}
}
Kostenlos starten →